Document:

Exhibit 4.3

  

   

  

   

  

   

  

  

  

  
    PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT

    

    

    MEDLAB CLINICAL LTD.

    

    

    	
            Warrant Shares: ___________

          	
            Original Issue Date: [_________], 2022

          

    

    

    THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”)
      certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the
      conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (Eastern time) on [  ], 2027 (the
      “Termination Date”) but not thereafter, to subscribe for and purchase from Medlab Clinical Ltd., a company organized under the laws of Australia (the “Company”), up to ______ Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”).
      The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Underwriting Agreement, dated [ ], 2022, between the Company and
      A.G.P./Alliance Global Partners, as representative of the underwriters thereunder (the “Underwriting Agreement”).

    

    

    Section 1. Definitions. In addition to the terms defined
      elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:

    

    

    “Affiliate” means any Person that, directly or indirectly
      through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.

    

    

    “Bid Price” means, for any date, the price determined by
      the first of the following clauses that applies: (a) if the Ordinary Shares are then listed or quoted on a Trading Market, the bid price of the Ordinary Shares for the time in question (or the nearest preceding date) on the Trading Market on which
      the Ordinary Shares are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (Eastern time) to 4:02 p.m. (Eastern time)), (b) if the Ordinary Shares are not then listed on a Trading Market, and if prices for the
      Ordinary Shares are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Ordinary Share so reported, or (c) in all
      other cases, the fair market value of a Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and
      expenses of which shall be paid by the Company.

    

    

    “Business Day” means any day except any Saturday, any
      Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

    

    

    “Commission” means the United States Securities and
      Exchange Commission.

    

    

    “Exchange Act” means the Securities Exchange Act of 1934,
      as amended, and the rules and regulations promulgated thereunder.

    

    

    “Ordinary Shares” means the ordinary shares of the Company,
      no par value, and any other class of securities into which such securities may hereafter be reclassified or changed.

    

    

    “Ordinary Share Equivalents” means any securities of the
      Company or its Subsidiaries, which would entitle the holder thereof to acquire at any time Ordinary Shares, including, without limitation, any debt, preferred shares, right, option, warrant or other instrument that is at any time convertible into or
      exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Ordinary Shares.

    “Person” means an individual or
      corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

    
      1

      
        

    

    

    

    

    

    “Registration Statement” means the Company’s registration
      statement on Form F-1 (File No. 333-267873), as amended, or such other replacement registration statement on the applicable Form that has been declared effective by the Commission.

    

    

    “Securities Act” means the Securities Act of 1933, as
      amended, and the rules and regulations promulgated thereunder.

    

    

    “Subsidiary” means any subsidiary of the Company and shall,
      where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.

    

    

    “Trading Day” means a day on which the Ordinary Shares are
      traded on the principal Trading Market.

    

    

    “Trading Market” means any of the following markets or
      exchanges on which the Ordinary Shares are listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, or the OTCQX or
      OTCQB markets (or any successors to any of the foregoing).

    

    

    “Transfer Agent” means Vstock Transfer, LLC, with a mailing
      address of 18 Lafayette Place, Woodmere, NY 11598, and any successor transfer agent of the Company.

    

    

    “VWAP” means, for any date, the price determined by the
      first of the following clauses that applies: (a) if the Ordinary Shares are then listed or quoted on a Trading Market, the daily volume weighted average price of the Ordinary Shares for such date (or the nearest preceding date) on the Trading Market
      on which the Ordinary Share are then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (Eastern time) to 4:02 p.m. (Eastern time)), (b) if the Ordinary Shares are not listed on a Trading Market, and if prices for
      the Ordinary Shares are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Ordinary Shares so
      reported, or (c) in all other cases, the fair market value of a Ordinary Share as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the
      Company, the fees and expenses of which shall be paid by the Company.

    

    

    “Warrants” means this Warrant and other pre-funded Ordinary
      Share purchase warrants issued by the Company pursuant to the Registration Statement.

    Section 2. Exercise.

    

    

    a) Exercise of Warrant. Exercise of the purchase rights
      represented by this Warrant may be made, in whole or in part, at any time or times on or after the Original Issue Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy (or .pdf copy via e-mail
      attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of
      Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice
      of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be
      required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
      the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days
      of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the
      outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such
      purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee,
        by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
        given time may be less than the amount stated on the face hereof.

    
      2

      
        

    

    

    

    

    

    b) Exercise Price. The exercise price per Warrant Share
      shall be $[  ], subject to adjustment hereunder (the “Exercise Price”).

    

    

    c) Cashless Exercise. If at any time after the Original
      Issue Date, there is no effective Registration Statement registering the Warrant Shares, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then the Holder may elect instead to exercise this
      Warrant, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:

    

    

    (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
      Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as
      defined in Rule 600(b)(77) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
      Exercise or (z) the Bid Price of the Ordinary Shares on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular
      trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the
      applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of “regular trading hours” on such Trading Day;

    

    

    (B) = the Exercise Price of this Warrant, as adjusted hereunder; and

    (X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this
      Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

    

    

    If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the
      Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position contrary to this Section 2(c).

    

    

    d) Mechanics of Exercise.

    

    

    i. Delivery of Warrant Shares Upon Exercise. The Company
      shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at
      Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective Registration Statement permitting the issuance of
      the Warrant Shares to or resale of the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or
      its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery
      to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the
      Notice of Exercise (such date, the “Warrant Share Delivery Date”). If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice
      of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Ordinary Shares on the date
      of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant
      Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Ordinary Shares as in
      effect on the date of delivery of the Notice of Exercise.

    
      3

      
        

    

    

    

    

    

    ii. Delivery of New Warrants Upon Exercise. If this
      Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the
      Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

    

    

    iii. Rescission Rights. If the Company fails to cause the
      Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise, including in the event of a Buy-In (as defined below), as
      described in Section 2(d)(iv) below.

    iv. Compensation for Buy-In on Failure to Timely
          Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
      2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise
      purchases, Ordinary Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
      then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the Ordinary Shares so purchased exceeds (y) the amount obtained by multiplying (1)
      the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of
      the Holder (pursuant to notice to be sent by the Holder to the Company within ten (10) days following the Warrant Share Delivery Date; if such notice is not provided by that date, the Company shall instead have the right to decide), either reinstate
      the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Warrant Shares that would have been issued had
      the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Ordinary Shares having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Warrant Shares
      with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
      indicating the amounts payable to the Holder in respect of the Buy-In and evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without
      limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Warrant Shares upon exercise of the Warrant as required pursuant to the terms hereof.

     

    

    v. No Fractional Shares or Scrip. No fractional shares or
      scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash
      adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

    

    

    vi. Charges, Taxes and Expenses. Issuance of Warrant
      Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall
      be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
      exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
      shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic
      delivery of the Warrant Shares.

    

    

    vii. Closing of Books. The Company will not close its
      shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

    viii. ASX Requirements.
      Notwithstanding any provision in this Warrant to the contrary, in no circumstances will the Company be required to issue Warrant Shares if to do so would, or would be reasonably likely in the opinion of the Company, to contravene any applicable laws
      including the Australian Corporations Act 2001 (“Corporations Act”) and the Listing Rules of the Australian Securities Exchange (“ASX”), as amended from time to time (the “ASX Listing Rules”).  On or before the Warrant Share Delivery Date, the
      Company shall, subject to the Corporations Act and the ASX Listing Rules:

    	

          	i.	
            lodge an Appendix 3B with the ASX in respect of the proposed issue of such Warrant Shares;

          

    
      	

            	ii.	
              issue and allot the Warrant Shares;

            

    

    
      	

            	iii.	
              lodge an Appendix 2A with the ASX in respect of the issue of such Warrant Shares; and

            

    

    	

          	iv.	
            either (a) issue a Cleansing Statement under the Corporations Act or (b) lodge a prospectus with the Australian Securities and Investments Commission under the Corporations
              Act which qualifies the Warrant Shares for resale under section 708A(11) of the Corporations Act or (c) obtain an exemption from Corporations Act to allow the immediate resale of the Warrant Shares, in each case in respect of such Warrant
              Shares.

          

    e) Holder’s Exercise Limitations. The
      Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set
      forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would cause the Attribution Parties to be in breach of the Corporations Act, including without limitation under section 606 of the Corporations Act, or would beneficially own in
      excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of Ordinary Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of Warrant
      Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of Warrant Shares which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant
      beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or non-converted portion of any other securities of the Company (including, without limitation, any other Ordinary
      Share Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for
      purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
      representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
      in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
      shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any
      Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In
      addition, a determination as to any group status as contemplated above shall be determined by the Holder in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in
      determining the number of outstanding Ordinary Shares, a Holder may rely on the number of outstanding Ordinary Shares as reflected in (A) the Company’s most recent periodic or annual report filed with or furnished to the Commission, as the case may
      be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Ordinary Shares outstanding. Upon the written or oral request of a Holder, the Company shall
      within one (1) Trading Day confirm orally and in writing to the Holder the number of Ordinary Shares then outstanding. In any case, the number of outstanding Ordinary Shares shall be determined after giving effect to the conversion or exercise of
      securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding Ordinary Shares was reported. The “Beneficial Ownership Limitation” shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of Ordinary Shares outstanding immediately after giving effect to the
      issuance of Warrant Shares issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation
      in no event exceeds 9.99% of the number of Ordinary Shares outstanding immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply.
      Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
      conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or
      desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

    
      4

      
        

    

    

    

    

    

    Section 3. Certain Adjustments. Notwithstanding any
      provision of this Section 3 or generally in this Warrant, the Exercise Price per Warrant, the number of Warrant Shares issuable upon exercise of this warrant, or the number of Warrants held shall be subject to adjustment from time to time after the
      Original Issue Date and in accordance with the ASX Listing Rules upon the occurrence of certain events described in this Section 3 or, if the ASX Listing Rules are amended after the date of issue of the Warrants, in accordance with the Company’s
      obligations under the ASX Listing Rules to the extent those obligations are modified by the amendment.

    

    

    a) Share Dividends and Splits. If the Company, at any time
      while this Warrant is outstanding: (i) subdivides outstanding Ordinary Shares into a larger number of shares, or (ii) combines (including by way of reverse share split) outstanding Ordinary Shares into a smaller number of shares, then in each case
      the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of
      Ordinary Shares outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged, provided that
      the Exercise Price per share shall in any case be no lower than the par value of the Ordinary Shares. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders
      entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

    b) Intentionally omitted.

    

    

    c) Intentionally omitted.

    

    

    d) Pro Rata Distributions. If there is a pro-rata offer of Ordinary Shares (other than a bonus issue) to the holders of Ordinary Shares, the Exercise Price will be reduced in accordance with the following formula:

     O’ = O - E [100 [P – (S + D)]]

                   N + 1

    

    

    Where:

    

    

    O’ is the new Exercise Price;

    

    

    O is the old Exercise Price;

    

    

    E is the number of Ordinary Shares into which one Warrant is exercisable;

    

    

    P is the volume weighted average market price per Ordinary Share on the ASX over the 5 ASX trading days
      ending on the ASX trading day before the ex rights or ex entitlement date for the pro rata issue;

    

    

    S is the subscription price for one Ordinary Share under the pro rata offer;

    

    

    D is the dividend (if any) due but not yet paid on an existing Ordinary Shares which will not be paid on
      the new Ordinary Shares to be issued in the pro rata issue;

    

    

    N is the number of Ordinary Shares that must be held on the record date for the pro rata issue to receive
      a right or entitlement to subscribe for one new Ordinary Share.

    

    

    For the avoidance of doubt, if the formula results in no decrease in the Exercise Price then the Exercise
      Price remains unchanged.

    
      5

      
        

    

    

    

    

    

    e) Fundamental Transaction.
      If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
      effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
      offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or
      more of the outstanding Ordinary Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant
      to which the Ordinary Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a share purchase agreement or other business
      combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Ordinary Shares
      (not including any Ordinary Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
      issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of Ordinary Shares of the
      successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable
      as a result of such Fundamental Transaction by a holder of the number of Warrant Shares for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
      Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share in
      such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Ordinary
      Shares are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following
      such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder’s option, exercisable at any time concurrently with, or
      within thirty (30) days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of
      cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided,
      however, if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be
      entitled to receive from the Company or any Successor Entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion
      of this Warrant, that is being offered and paid to the holders of Ordinary Shares of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, shares or any combination thereof, or whether the
      holders of Ordinary Shares are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Ordinary Shares of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Ordinary Shares will
      be deemed to have received Ordinary Shares of the Successor Entity (which may be the Company following such Fundamental Transaction) in such Fundamental Transaction. “Black
          Scholes Value” means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on Bloomberg, L.P. (“Bloomberg”)
      determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
      announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor)
      as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being
      offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the
      applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder’s request pursuant to this Section 3(e), and (D) a remaining option time equal to the time
      between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available
      funds (or such other consideration) within the later of (i) five Business Days of the Holder’s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in
      which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant in accordance with the
      provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this
      Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its
      parent entity) equivalent to the Warrant Shares acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which
      applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of
      capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the
      Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the “Company”
      shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the
      Company herein.

    
      6

      
        

    

    

    

    

    

    g) Calculations. All calculations under this Section 3
      shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary
      Shares (excluding treasury shares, if any) issued and outstanding.

    

    

    h) Notice to Holder.

    

    

    i. Adjustment to Exercise Price. Whenever the Exercise
      Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of
      Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

    

    

    ii. Notice to Allow Exercise by Holder. If (A) the
      approval of any shareholders of the Company shall be required in connection with any reclassification of the Ordinary Shares, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets
      of the Company, or any compulsory share exchange whereby the Ordinary Shares are converted into other securities, cash or property, or (B) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
      of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 5 calendar days prior
      to the applicable record or effective date hereinafter specified, a notice stating the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it
      is expected that holders of the Ordinary Shares of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
      provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice and provided, further that no notice shall be required if
      the information is disseminated in a press release or document filed with the Commission. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the
      Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the
      effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

    Section 4. Transfer of Warrant.

    

    

    a) Transferability. This Warrant and all rights hereunder
      (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant
      substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company
      shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
      the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has
      assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant,
      if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

    
      7

      
        

    

    

    

    

    

    b) New Warrants. This Warrant may be divided or combined
      with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject
      to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
      with such notice. All Warrants issued on transfers or exchanges shall be dated the Original Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

    

    

    c) Warrant Register. The Company shall register this
      Warrant, upon records to be maintained by the  Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The
      Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

    

    

    Section 5. Miscellaneous.

    

    

    a) No Rights as Shareholder Until Issue. This Warrant does
      not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the issue of Warrant Shares following exercise hereof as set forth in Section 2(d)(i). This Warrant does not confer the right to
      participate in new issues of Shares without exercising this Warrant.

    

    

    b) Loss, Theft, Destruction or Mutilation of Warrant. The
      Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any share certificate relating to the Warrant Shares, and in case of loss, theft or
      destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or share certificate, if mutilated, the Company
      will make and deliver a new Warrant or share certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or share certificate.

    

    

    c) Saturdays, Sundays, Holidays, etc. If the last or
      appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

    d) Authorized Shares.

    The Company and the Holder acknowledge and agree that the Company must first obtain the approval from the holders of its
      Ordinary Shares for the issuance of any Ordinary Shares upon the exercise of any Purchase Warrants if the number of Ordinary Shares to be issued exceeds the limits prescribed by ASX Listing Rule 7.1 and 7.1A. The Company further covenants that its
      issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
      action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Ordinary Shares may be listed. The
      Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
      accordance herewith, be duly authorized, validly issued, fully paid and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
      issue).

    

    

    Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
      limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
      performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in
      this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par
      value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such
      authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

    
      8

      
        

    

    

    

    

    

    Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is
      exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

    

    

     e) ASX Filings. The Company will ensure that it applies
      to ASX for official quotation (as that expression is used in the ASX Listing Rules) of the Ordinary Shares issued on the exercise of the Warrants in the same class and on the same terms as all other Ordinary Shares quoted on ASX pursuant to ASX
      Listing Rule 2.7 within five business days on issue of those Ordinary Shares.

    

    

    f) Governing Law. All questions concerning the
      construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each
      party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
      shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
      sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in
      any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives
      personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in
      effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other
      manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
      attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.

    g) Restrictions. The Holder acknowledges
      that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

    

    

    h) Non-waiver and Expenses. No course of dealing or any
      delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company
      willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
      not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

    
      9

      
        

    

    

    

    

    

    i) Notices. Any notices, consents, waivers or other
      document or communications required or permitted to be given or delivered under the terms of this Warrant, including, without limitation, any Notice of Exercise, must be in writing and will be deemed to have been delivered: (i) upon receipt, if
      delivered personally; (ii) when sent, if sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); (iii) when sent, if sent by e-mail (provided that such sent e-mail
      is kept on file (whether electronically or otherwise) by the sending party and the sending party does not receive an automatically generated message from the recipient’s e-mail server that such e-mail could not be delivered to such recipient) and
      (iv) if sent by overnight courier service, one (1) Trading Day after deposit with an overnight courier service with next day delivery specified, in each case, properly addressed to the party to receive the same. The addresses, facsimile numbers and
      e-mail addresses for such communications shall be:

    

    

    If to the Company:

    

    

    Medlab Clinical Ltd.

    Units 5 and 6, 11-13 Lord Street

    Botany, New South Wales 2019

    Attention: Dr. Sean Hall, Chief Executive Officer

    Telephone number: + 61 8188 0311

    Email address: sean_hall@medlab.com

    

    

    with a copy (which shall not constitute notice) to:

    
      

      

      Seward & Kissel LLP

      One Battery Park Plaza

      New York, NY 10004

      Attention: Edward S. Horton

      Email: horton@sewkis.com

    

    

    

    If to a Holder, to its address, facsimile number or e-mail address set forth herein or on the books and records of the Company.

    

    

    j) Limitation of Liability. No provision hereof, in the
      absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any
      Warrant Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

    

    

    k) Remedies. The Holder, in addition to being entitled to
      exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason
      of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

    l) Successors and Assigns. Subject to
      applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The
      provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

    

    

    m) Amendment. This Warrant may be modified or amended or
      the provisions hereof waived with the written consent of the Company on the one hand, and the Holder or the beneficial owner of this Warrant, on the other hand.

    

    

    n) Severability. Wherever possible, each provision of this
      Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such
      prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

    

    

    o) Headings. The headings used in this Warrant are for the
      convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

    

    

    ********************

    (Signature Page Follows)

    
      10

      
        

    

    

    

    IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the
      date first above indicated.

     

    

    	 	
            MEDLAB CLINICAL LTD.

          
	 	 	 
	 	
            By:

          	 
	 	
            Name:

          	
             Sean Hall

          
	 	
            Title:

          	
             Chief Executive Officer

          

    

    

    
      11

      
        

    

    

    

    EXHIBIT A

    

    

    NOTICE OF EXERCISE

    

    

    TO: MEDLAB CLINICAL LTD.

    

    

    (1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
        tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

    (2) Payment shall take the form of (check applicable box):

    [  ] in lawful money of the United States; or

    [ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set
      forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

    (3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

    

    

    	 	 	 
	 	 	 

    

    

    

    

    The Warrant Shares shall be delivered to the following DWAC Account Number:

    

    

    	 	 	 
	 	 	 
	 	 	 

    

    

    

    

    (4)  Accredited Investor.  The undersigned is an “accredited
      investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

    

    

    [SIGNATURE OF HOLDER]

    

    

    	
            Name of Investing Entity:

          	 
	
            Signature of Authorized Signatory of Investing Entity:

          	 
	
            Name of Authorized Signatory:

          	 
	
            Title of Authorized Signatory:

          	 
	
            Date:

          	 
	 	 
	 	 

    

    

    

    

    
      12

      
        

    

    

    

    EXHIBIT B

    

    

    ASSIGNMENT FORM

    

    

    (To assign the foregoing Warrant, execute this form and supply required information.  Do
      not use this form to purchase shares.)

    FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

    

    

    	
            Name:

          	 	 	 
	 	 	
            (Please Print)

          
	 	 	 
	
            Address:

          	 	 	 
	 	 	
            (Please Print)

          
	 	 	 
	
            Phone Number:

          	 	 	 
	 	 	 
	
            Email Address:

          	 	 	 
	 	 	 
	
            Dated: _______________ __, ______

          	 	 
	 	 	 
	
            Holder’s Signature: ___________________

          	 	 
	 	 	 
	
            Holder’s Address: ________________________

          	 	 
	 	 	 

    

    

    

    

    

    

  

  13Exhibit 10.1

  

  

    

  

  
    

    

    

    

    

    Collaborative Research Agreement

    

    

    

    

    	
             

            PARTIES

             

          
	
             

            UNSW

             

          	
             

            The University of New South Wales ABN 57 195 873 179, a body corporate established pursuant to the University of New South
                Wales Act 1989 (NSW) of UNSW Sydney NSW 2052, Australia

             

          
	
             

            Collaborating Organisation(s)

             

          	
             

            The party or parties with contact details specified in Schedule 1.

             

          
	
             

            Partner Organisation(s)

             

          	
             

            The party or parties with contact details specified in Schedule 1.

             

          
	 	  
	
             

            DETAILS

             

          
	
             

            KEY DATES

             

          
	
             

            Project Start Date (clause 1)

             

          	
             

            On the date the last party signs this agreement.

             

          
	
             

            Project Completion Date (clause 1)

             

          	
             

            23 December 2022

             

          
	
             

            PROJECT

             

          
	
             

            Project (clause 1)

             

          	
            mRNA nanocell delivery system

             

            Milestones:

            • End of month 3 = first batch
                of siRNA ready for formulation experiments

            • End of month 6 = first
                nanocell-siRNA formulation ready for in vitro testing (RPMI cells), > 10 mg siRNA batch ready

            • End of month 9 = physical
                characterisation of nanocell-siRNA formulation completed (size, loading), stability studies initiated (before/after actuation)

            • End of month 12 = in vitro RPMI tests completed, stability studies completed

             

          
	
             

            Project Plan (clause 1.2(a))

             

          	
             

             ☒ Attached at Schedule 3; or

             ☐  As above under ‘Project’.

             

          
	
             

            Ethics/biosafety approval required (clause 1.6)

             

          	
             ☐  YES  ☒ NO

             

          

    

    

    
      Page 1

      
        

    

    
      
        Collaborative Research Agreement
          

        

        

      

    

    
      

      

      Recitals

      	A.	
              UNSW, together with the Collaborating Organisations, has been engaged by the Partner Organisation to undertake the Project

            

      

      

      	B.	
              The Partner Organisation has agreed to make their Total Contributions to UNSW in connection with the Project.

            

      

      

      	C.	
              The Parties agree to conduct the Project on the terms of this agreement.

            

      Terms

      
        	

              	1.	
                The Project

              

        
          

        

        

      

      	1.1	
              The parties must:

            

      	

            	(a)	
              start the Project on the Project Start Date; and

            

      	

            	(b)	
              use reasonable endeavours to complete the Project on or near the Project Completion Date or such other date as may be agreed by the parties.

            

      	1.2	
              The parties must carry out the Project:

            

      	

            	(a)	
              in accordance with the Details and the Project Plan;

            

      	

            	(b)	
              using Specified Personnel;

            

      	

            	(c)	
              with due skill and care in accordance with generally accepted professional, scientific and ethical principles and standards applicable to the Project; and

            

      	

            	(d)	
              in compliance with all applicable laws and regulations.

            

      	1.3	
              The parties acknowledge that research work is of its nature uncertain and that particular outcomes or results from the Project cannot be guaranteed.  No party will be liable to any other party for any loss or damage whether arising from
                that party’s failure to perform work on time or within the estimated costs of the Project or otherwise provided that party has used its reasonable endeavours in all respects in carrying out the Project.

            

      	1.4	
              The parties acknowledge that the Project may require approval by an institutional ethics and/or biosafety committees (or similar) of UNSW or the Collaborating Organisation(s).  The relevant party must use reasonable endeavours to
                promptly obtain that approval.  Before such approvals are obtained, the parties are not required to commence the Project.

            

      	1.5	
              UNSW and the Collaborating Organisation(s) must maintain complete and accurate records regarding the conduct and conclusions of the Project.

            

      
        Page 2

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      
        

        

        	

              	2.	
                Not Used

              

        
          

        	

              	3.	
                General obligations

              

        
          

        

        

      

      	3.1	
              Each party must:

            

      	

            	(a)	
              perform its Project Obligations;

            

      	

            	(b)	
              co-operate with each other party and provide all other assistance, Material, equipment, facilities, resources as may be reasonably necessary to perform the Project; and

            

      	

            	(c)	
              ensure that it and its employees and the employees of its subcontractors (if any) comply with each other party’s usual staff, safety and security practices while attending that party’s premises, as notified by that party or as might
                reasonably be inferred from the use of the premises.

            

      	3.2	
              No party may make any representation to the effect that a party has evaluated, tested, recommended, approved or endorsed any product or service, without the relevant party’s consent.

            

      	3.3	
              A party may only subcontract its obligations under this Agreement to a third party with the prior written consent of each other party. If each other party consents to a party subcontracting in accordance with this clause, the party who
                subcontracts remains primarily responsible for its obligations under this agreement.

            

      
        	

              	4.	
                Contributions

              

        
          

        

        

      

      	4.1	
              Each party must provide its Total Contribution to the Project.

            

      	4.2	
              The Partner Organisation(s) must pay the Cash Contribution to UNSW:

            

      	

            	(a)	
              in relation to the first instalment, promptly after the Project Start Date; and

            

      	

            	(b)	
              in relation to each subsequent instalment, as per Payment Milestones specified in Schedule 2,

            

      following receipt of a Tax Invoice from UNSW.

      	4.3	
              UNSW must pay the Collaborating Organisation(s) the amounts and in the manner specified in Schedule 2, subject to UNSW receiving sufficient Cash Contributions from the Partner Organisation(s).

            

      	4.4	
              Unless specified otherwise, all monetary amounts expressed in this agreement are exclusive of GST.

            

      	4.5	
              A party must pay to the relevant party the amount specified on each Tax Invoice issued in accordance with clauses 4.2 or 4.3 by the due date specified on the Tax Invoice or if no due date is specified, within 30 days after the Tax
                Invoice is issued.

            

      	4.6	
              If any supply under this agreement is a Taxable Supply, the party making the supply may, in addition to any payment for the supply, recover the amount of the GST applicable to the supply.

            

      	4.7	
              Any amount of GST payable for a supply will be payable at the same time as the payment for the supply to which it relates.

            

      
        Page 3

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      
        

        

        	

              	5.	
                Project Management

              

        
          

        

        

      

      	5.1	
              Unless otherwise agreed between the parties, as soon as reasonably practicable after the Project Start Date, the parties must establish a Management Committee comprising:

            

      	

            	(a)	
              2 nominees from UNSW;

            

      	

            	(b)	
              2 nominees from the Collaborating Organisation(s); and

            

      	

            	(c)	
              up to 2 nominees from the Partner Organisation(s).

            

      	5.2	
              A member of the Management Committee nominated by UNSW will chair the Management Committee.

            

      	5.3	
              The Management Committee will have general oversight of the conduct of the Project, including matters relating to the progress, direction and results of the Project and any disclosure of Project Intellectual Property.

            

      	5.4	
              The Management Committee will promptly report to UNSW any Project Intellectual Property developed during the Project.

            

      	5.5	
              The following matters may be considered at the first meeting of the Management Committee:

            

      	

            	(a)	
              frequency and format of meetings to discuss the progress of the Project;

            

      	

            	(b)	
              obligations to take and keep minutes of meetings;

            

      	

            	(c)	
              protocols for making decisions in relation to the conduct of the Project; and

            

      	

            	(d)	
              protocols for identifying, protecting and disclosing Project Intellectual Property.

            

      	5.6	
              The Management Committee may conduct its meetings by teleconference or videoconference.  The Management Committee may make decisions and take action as required under this agreement to carry out the Project.  The decision of a majority
                of the members of the Management Committee will be binding.  In the event of an even number of votes, the chair will have the deciding vote.

            

      	5.7	
              To avoid doubt, the Management Committee does not have the power to make any decisions in relation to Intellectual Property Rights or vary this agreement including to vary:

            

      	

            	(a)	
              the Total Contributions; or

            

      	

            	(b)	
              content or scope of the Project.

            

      
        	

              	6.	
                Assets

              

        
          

        

        

      

      	6.1	
              Except as stated otherwise in the Project Plan, any Asset purchased wholly or partly with the Funds is owned by UNSW.

            

      	6.2	
              For the term of this agreement, each owner of Assets contributed to or acquired for the Project:

            

      	

            	(a)	
              must make the Asset available for use by UNSW and the Collaborating Organisation(s) for purpose of the Project, as reasonably required;

            

      	

            	(b)	
              must not sell, hire, charge, mortgage or otherwise encumber the Asset; and

            

      	

            	(c)	
              is responsible for insurance, maintenance and, if required, repair and replacement of the Asset and any other costs and liabilities associated with the Asset.

            

      
        Page 4

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      
        

        

        	

              	7.	
                Intellectual Property

              

        
          

        

        

      

      	7.1	
              Each party grants to the other parties a non-exclusive, irrevocable, non-transferable, royalty-free licence for the duration of the Project to use their Background Intellectual Property solely for the purpose of conducting the Project. A
                party must not reverse engineer the other party’s Background Intellectual Property.

            

      	7.2	
              Except as otherwise specified in this agreement, each party acknowledges that nothing in this agreement assigns or grants any other rights to another party in any Background Intellectual Property.

            

      	7.3	
              The parties must use reasonable endeavours to ensure that their Specified Personnel promptly notify each other upon creation of Project Intellectual Property.

            

      	7.4	
              Subject to the Partner Organisation making its Total Contributions to UNSW, all Project IP will be jointly owned by the Parties as tenants in common in equal shares (except that a Student owns copyright in his/her thesis).  Each party
                assigns to the other parties an equal share of its right, title and interest in Project IP and agrees to do all things reasonably necessary to give effect to such ownership and assignment (including ensuring its employees, contractors,
                agents and students do the same).

            

      	7.5	
              Each Party grants to each other party an irrevocable, non-transferable, non-exclusive, free of cost licence (not including a right to sub-licence) to use the Project IP for the purposes of conducting the Project for the duration of the
                Project and for its own internal non-commercial purposes following completion of the Project.

            

      	7.6	
              The Parties shall consult with each one another as to whether any Project IP should be Commercialised. To the extent that any Project IP is capable of commercialisation, a commercialisation strategy will be agreed in good faith by the
                owners with the intention that commercialisation revenue is equally shared between the owners.

            

      
        	

              	8.	
                Confidentiality and privacy

              

        
          

        

        

      

      	8.1	
              Each party:

            

      	

            	(a)	
              may use Confidential Information of each other party solely for the purposes of this agreement;

            

      	

            	(b)	
              except as permitted under clause 8.1(c), must keep confidential all Confidential Information of each other party; and

            

      	

            	(c)	
              may disclose Confidential Information of each other party only to employees, contractors and Students who:

            

      	

            	(i)	
              are aware and agree that the Confidential Information of each other party must be kept confidential; and

            

      	

            	(ii)	
              either have a need to know (and only to the extent that each has a need to know), or have been specifically approved by that other party.

            

      	8.2	
              If a party wants to disclose another party’s Confidential Information to a person other than that other party, its employees, contractors or Students (Third Person), that party must require the
                Third Person to enter into a confidentiality agreement on substantially similar terms to those confidentiality requirements specified in clause 8.1.

            

      	8.3	
              Each party must comply with the reasonable directions of each other party in relation to the handling of any Personal Information that the party holds or has held.

            

      
        Page 5

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      
        

        

        	

              	9.	
                Publications

              

        
          

        

        

      

      	9.1	
              Each party is entitled to Publish the results of the Project provided that no Confidential Information owned by a non-publishing party is disclosed.

            

      	9.2	
              The publishing party must provide each other party with a copy of any Publication.

            

      
        	

              	10.	
                Students

              

        
          

        

        

        

        

      

      	10.1	
              Parties who have enrolled Students who are involved in the Project agree that:

            

      	

            	(a)	
              they must ensure that those Students comply with clause 8;

            

      	

            	(b)	
              they must ensure that Project Intellectual Property developed by the Student is owned in accordance with clause 7, provided that the Student will own the copyright in his or her thesis;

            

      	

            	(c)	
              the only restrictions on publishing a Student’s thesis will be those reasonably necessary to protect Confidential Information or the Project Intellectual Property (which in any case must be no longer than 12 months after completion of
                the Project);

            

      	

            	(d)	
              the parties must not inhibit the right of a Student to have his or her thesis examined, but an examiner may be required to sign a confidentiality agreement to protect Confidential Information; and

            

      	

            	(e)	
              before a Student becomes involved in the Project, the parties may require that the Student and the institution in which the Student is enrolled enter into a written agreement, in a form approved by UNSW, setting out the terms on which
                the Student is involved in Project, which must be consistent with the principles in this clause 10.

            

      
        	

              	11.	
                Indemnity, warranties and limitations on liability

              

        
          

        

        

        

        

      

      	11.1	
              The parties exclude:

            

      	

            	(a)	
              from this agreement all conditions, warranties and terms implied by statute, general law or custom, except those that cannot be excluded in law (Non‐excludable Conditions) such as certain
                warranties under the Competition and Consumer Act 2010 (Cth);

            

      	

            	(b)	
              all liability to each other in contract for consequential or indirect damages suffered by the parties, lost profit, loss of anticipated savings or business or goodwill, claims by any third parties or costs and expenses associated with or
                incidental to any of the preceding examples, arising out of, or in connection with, the Project and this agreement even if the parties knew they were possible or they were otherwise foreseeable; and

            

      	

            	(c)	
              all liability to each other in negligence or other non-contractual causes of action in respect of which liability can be excluded for acts or omissions of their respective employees, agents, contractors and Students arising out of or in
                connection with this agreement.

            

      	11.2	
              To the extent permitted by law, a party’s total liability to the other parties for breach of a Non-excludable Condition is limited to any one of the following options:

            

      	

            	(i)	
              supplying, replacing or repairing the goods;

            

      	

            	(ii)	
              paying the cost of supplying, repairing, or replacing the goods;

            

      	

            	(iii)	
              supplying again; or

            

      	

            	(iv)	
              paying the cost of supplying again, the services in respect of which the breach occurred.

            

      
        Page 6

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      	11.3	
              Subject to clause 11.2, the total liability of a party otherwise in connection with this agreement or the Project for loss or damage of any kind whether arising in contract, tort (including negligence), equity, under statute or otherwise
                is limited to the amount equivalent to the Total Contribution of that party.

            

      	11.4	
              Subject to clause 11.2, each party’s liability under this agreement is reduced to the extent that any damage, liability, loss or cost arises from or is attributable to any act or omission of the other party (or parties), its employees,
                agents, contractors or Students.

            

      	11.5	
              Subject to clause 11.1 to 11.4 (inclusive), each party (Indemnifier) indemnifies the other party and its officers, employees, subcontractors, agents and Students (together, ‘those Indemnified’), and agrees to keep them indemnified, against all liability, loss, costs, damages or expense that those Indemnified may suffer or  incur, as a result of wilful misconduct, negligent act or
                omission, or unlawful act or omission on the part of the Indemnifier or its officers, employees, students, subcontractors or agents connected with this agreement.

            

      
        	

              	12.	
                Insurance

              

        
          

        

        

        

        

      

      	12.1	
              Each party must take out, maintain and keep current, at its own cost:

            

      	

            	(a)	
              workers compensation insurance in accordance with applicable law and awards;

            

      	

            	(b)	
              public liability insurance appropriate to the party’s activities for an amount not less than $10 million; and

            

      	

            	(c)	
              professional indemnity insurance for an amount not less than $5 million in respect of a claim for breach of professional duty whether incurred in contract, tort or otherwise or by reason of any act or omission of the party.

            

      	12.2	
              On request, a party must provide evidence to the other parties of the terms and currency of all insurance policies required under this agreement.

            

      	12.3	
              A party may act as its own insurer but only to the extent that it will be able to adequately meet its obligations under this agreement.

            

      
        	

              	13.	
                Dispute resolution

              

        
          

        

        

      

      	13.1	
              No party may start arbitration, tribunal or court proceedings (except proceedings seeking interlocutory relief in a court of competent and applicable jurisdiction) in respect of a Dispute unless it has first complied with this clause.

            

      	13.2	
              The parties will use its best endeavours to co-operatively resolve a Dispute.

            

      	13.3	
              A party claiming that a Dispute has arisen must notify the other parties in writing.  The Dispute must then be referred immediately to the Vice-Chancellor (or delegate) of UNSW and the Collaborating Organisation(s) and General Manager or
                equivalent of the Partner Organisation(s) for resolution.

            

      	13.4	
              If the Dispute is not resolved within three days of such referral, the Dispute will be referred to a panel (Panel) for resolution.  Each party to the Dispute must nominate a senior representative
                for the Panel within three days of the referral to the Panel in accordance with this clause.

            

      	13.5	
              If a Dispute is referred to the Panel in accordance with clause 13.4, the Panel will meet to resolve the Dispute unless the Panel agrees to resolve the Dispute without need for a meeting.

            

      
        Page 7

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      	13.6	
              The Panel may determine its own procedures for meetings.  Decisions of the Panel may only be made by unanimous agreement of the members of the Panel.  Any decision of the Panel will be final and binding on the parties and will be
                provided in writing to the parties.

            

      	13.7	
              If the Panel does not resolve the Dispute within ten days after the Dispute being referred to the Panel, then the Dispute must be referred to mediation in accordance with clauses 13.8 to 13.10.

            

      	13.8	
              The mediator may be appointed either by agreement or failing such agreement within five days after expiry of the period set out in clause 13.7, by reference to the President of the Law Society of New South Wales who will nominate a
                mediator.

            

      	13.9	
              The parties agree that:

            

      	

            	(a)	
              each party will bear their respective costs of the mediation save that the mediator’s fee, fees for mediation rooms and costs of shares equipment facilities and services of the mediation will be shared equally;

            

      	

            	(b)	
              the venue for the mediation will be agreed between the parties or, failing such agreement, will be nominated by the mediator;

            

      	

            	(c)	
              each party may be legally represented if they so wish; and

            

      	

            	(d)	
              the mediation will be conducted without prejudice and complete confidentiality will be preserved in respect of the mediation and any documents and information used at or in relation to the mediation.

            

      	13.10	
              If the Dispute or difference has not been resolved or mediated within 90 days after receipt of the notice specified in clause 13.3, a party may terminate the dispute resolution process by giving written notice to the other parties.

            

      	13.11	
              Prior to the resolution of a Dispute, each party must continue to perform its obligations under this agreement.

            

      
        	

              	14.	
                Term and Termination

              

        
          

        

        

      

      	14.1	
              This agreement commences on the Project Start Date and expires three (3) months after the Project Completion Date unless the agreement is terminated earlier in accordance with this clause 14.

            

      	14.2	
              The parties may immediately terminate this agreement by mutual consent in writing.

            

      	14.3	
              If:

            

      	

            	(a)	
              a party breaches any material term of this agreement not capable of remedy;

            

      	

            	(b)	
              a party breaches any material term of this agreement capable of remedy and fails to remedy the breach within 30 days after receiving written notice requiring it to do so; or

            

      	

            	(c)	
              any event of insolvency occurs in relation to the Partner Organisation(s) (whether or not notified), including any step to appoint a receiver, administrator, trustee in bankruptcy or liquidator,

            

      then:

      	

            	(d)	
              the other party or parties may terminate this agreement in writing; or

            

      	

            	(e)	
              the other party or parties may terminate the defaulting or insolvent party’s involvement in the Project and continue to perform the Project.

            

      
        Page 8

        
          

      

      
        
          
            

            

            Collaborative Research Agreement
              

            

            

          

        

        

        

        

        

        	

              	15.	
                Consequences of termination

              

        
          

        

        

        

        

      

      	15.1	
              On termination:

            

      	

            	(a)	
              UNSW will be entitled to cease expenditure on the Project and be entitled to payment of costs and expenses that have been incurred or committed for the Project as at the effective date of termination which will not exceed the amount
                equivalent to the Total Contribution of the other parties for the year in which termination occurs;

            

      	

            	(b)	
              if requested by a party (Requesting Party), the other parties must return to the Requesting Party all:

            

      	

            	(i)	
              Background Intellectual Property of the Requesting Party in the other party’s possession or control; and

            

      	

            	(ii)	
              Confidential Information of the Requesting Party in material form (including those parts of all notes or records of the other party containing Confidential Information of the Requesting Party) in the other party’s possession or control;
                and

            

      	

            	(iii)	
              Property in their possession belonging to another party, and

            

      	

            	(c)	
              if a party terminates this agreement under clause 2, the defaulting party must pay any reasonable costs incurred by the other party or parties directly attributable to the termination of this agreement.

            

      	15.2	
              Clauses 1.3, 3.2, 6 ‐ 13 (inclusive) and 15 and all clauses required to give them effect survive the expiration or termination of this agreement.

            

      
        	

              	16.	
                Notices

              

        
          

        

        

      

      	16.1	
              A party giving notice or notifying under this agreement must do so in writing:

            

      	

            	(a)	
              directed to the recipient’s address specified in the Schedule 1 as altered by any written notice; and

            

      	

            	(b)	
              hand delivered or sent by prepaid post or email to that address.

            

      	16.2	
              A notice given in accordance with this clause is taken to be received:

            

      	

            	(a)	
              if hand delivered, on delivery;

            

      	

            	(b)	
              if sent by prepaid post, 3 days after the date of posting; or

            

      	

            	(c)	
              if sent by email, when the email has entered the recipient’s server.

            

      
        	

              	17.	
                Force Majeure Event

              

        
          

        

        

      

      	17.1	
              If a party (First Party) is partially or wholly precluded from complying with its obligations under this agreement by Force Majeure Event affecting the First Party, then the First Party’s
                obligation to perform in accordance with this agreement will be suspended for the duration of the delay arising out of the Force Majeure Event.

            

      	17.2	
              As soon as possible after a Force Majeure Event arises, the First Party must, if it has not already done so, notify the other parties of the:

            

      	

            	(a)	
              Force Majeure Event;

            

      	

            	(b)	
              extent to which the First Party is unable to perform its obligations under this agreement; and

            

      	

            	(c)	
              likely duration of the First Party’s inability to perform.

            

      	17.3	
              If the Force Majeure Event affecting the First Party is likely to or does continue for 60 days or more, the other parties may terminate this agreement within immediate or later effect by giving the First Party written notice.

            

      
        Page 9

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      
        

        

        	

              	18.	
                No waiver

              

        
          

        

        

      

      	18.1	
              A party’s agreement to waive a right or entitlement under this agreement is only effective if that party gives written notice of that waiver to the party seeking the benefit of the waiver.

            

      	18.2	
              Waiver by a party of anything that another party must do under this agreement is not a waiver of any other right or entitlement under this agreement.

            

      	18.3	
              A failure or delay in exercising a right arising from a breach of this agreement is not a waiver of that right.

            

      
        	

              	19.	
                General

              

        
          

        

        

      

      	19.1	
              This agreement may only be varied in writing by all the parties.

            

      	19.2	
              A party must not assign its rights or obligations under this agreement without the prior written consent of the other parties except that UNSW may assign its rights and obligations under this agreement to NSi by written notice to the
                other parties.

            

      	19.3	
              This agreement constitutes the entire agreement between the parties in relation to its subject matter and supersedes any previous agreement of the parties, or any other communication or representation made, in relation to its subject
                matter.

            

      	19.4	
              If a provision of this agreement is invalid, illegal or unenforceable, then to the extent of the invalidity, illegality or unenforceability, that provision must be ignored in the interpretation of this agreement.  All other provisions of
                this agreement remain in full force and effect.

            

      	19.5	
              Nothing in this agreement creates a relationship of employer and employee, principal and agent, or partnership between the parties.  A party has no authority to act for any other party or to create or assume a responsibility for an
                obligation of any other party.

            

      	19.6	
              A party may execute this agreement by signing a counterpart.  All counterparts constitute one document when taken together. A signed copy of this agreement made by photocopy, facsimile or PDF Adobe format will be considered an original
                and execution of this agreement will have occurred when each party holds such copy signed by the other party or parties to this agreement.

            

      	19.7	
              Each party must:

            

      	

            	(a)	
              do or cause to be done all acts and things necessary or desirable to give effect to; and

            

      	

            	(b)	
              refrain from doing all acts and things that could hinder performance by any party of,

            

      this agreement.

      	19.8	
              This agreement is governed by and must be construed in accordance with the laws of New South Wales.  Each party:

            

      	

            	(a)	
              irrevocably and unconditionally submits to the non-exclusive jurisdiction of the courts of New South Wales and all courts that have jurisdiction to hear appeals from them; and

            

      	

            	(b)	
              waives any right to object to proceedings being brought in those courts for any reason.

            

      
        Page 10

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      
        

        

        	

              	20.	
                Definitions and Interpretation

              

        
          

        

        

      

      	20.1	
              In this agreement:

            

      Asset means an item of real or personal
          property but does not include Intellectual Property Rights;

      Background Intellectual Property means
          Intellectual Property Rights owned by or licensed to a party as at the Project Start Date, or acquired or developed by a party during the course of the Project independently of the Project, which that party has the right to license to third
          parties and which are necessary for the performance of the Project, including those specified in Schedule 2 or as subsequently notified in writing by the parties;

      Cash Contribution means the cash component of
          the Total Contribution;

      Confidential Information means all know how,
          financial information and other commercially valuable information in whatever form including unpatented inventions, trade secrets, formulae, graphs, drawings, designs, biological materials, samples, devices, models and other materials of whatever
          description which a party claims is confidential to itself and over which it has full control and includes all other such information that may be in the possession of a party’s employees or management.  Information is not confidential if:

      	

            	(a)	
              it is or becomes part of the public domain unless it came into the public domain by a breach of confidentiality;

            

      	

            	(b)	
              it is obtained lawfully from a third party without any breach of confidentiality;

            

      	

            	(c)	
              it is already known by the recipient party (as shown by its written record) before the date of disclosure to it;

            

      	

            	(d)	
              it is independently developed by an employee of the recipient party who has no knowledge of the disclosure under this Agreement;

            

      	

            	(e)	
              required to be disclosed by a court, rule or governmental law or regulation, or the rules of any stock exchange, provided that the party making the disclosure provides prompt written notice to the other party of any such requirement; or

            

      	

            	(f)	
              it is required to be disclosed pursuant to this agreement.

            

      Details means the matters set out in the table
          on the front page(s) of this agreement;

      Dispute means a dispute arising out of or
          relating to this agreement including a dispute about the breach, termination, validity, or subject matter of this agreement, or a claim in equity or in tort relating to the performance or non-performance of this agreement;

      Force Majeure Event affecting a party means a
          circumstance beyond the reasonable control of that party causing that party to be unable to observe or perform on time an obligation under this agreement, including:

      	

            	(a)	
              acts of God, lightning strikes, earthquakes, floods, storms, explosions, fires and any natural disaster; and

            

      	

            	(b)	
              acts of public enemies, terrorism, riots, civil commotion, malicious damage, sabotage, revolution and acts of war and war, general strikes, embargo and power, water or other utility shortage;

            

      GST has the same meaning as in the GST Law;

      
        Page 11

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      GST Law has the same meaning as in the A New Tax System (Goods and Services Tax) Act 1999 (Cth) as amended or replaced from time to time;

      In-kind Contribution means the in-kind
          component of the Total Contribution;

      Intellectual Property Rights means all rights
          resulting from intellectual activity whether capable of protection by statute, common law or in equity, including copyright, discoveries, inventions, innovations, technical information and data, prototypes, processes, specifications, know‐how,
          patent rights, registered and unregistered trade marks, design rights, circuit layouts, plant varieties, the right to have confidential information kept confidential and all rights and interests of a like nature, together with any and all
          documentation and other material relating to such rights and interests;

      Management Committee means the management
          committee for the Project established under clause 5;

      Material means all materials in any form
          including all data, information, records, documents, databases and software (including source code and object code), other works and material and the subject matter of any category of Intellectual Property Rights;

      Moral Rights means all present and future
          rights of integrity of authorship, rights of attribution of authorship, rights not to have authorship falsely attributed, and rights of a similar nature conferred by statute anywhere in the world;

      NSi means NewSouth Innovations Pty Limited (ABN
          25 000 263 025) a wholly owned subsidiary of UNSW responsible for managing and for entering into agreements in relation to Commercialisation of UNSW’s Intellectual Property;

      Panel has the meaning in clause 13.4;

      Personal Information means information or an opinion (including information or an opinion forming part of a database), whether true or not, and whether recorded in a material form or not, about an
          individual whose identity is apparent, or can reasonably be ascertained, from the information or opinion;

      Publication means to publish by way of a paper,
          article, manuscript, report, poster, internet posting, presentation slides, abstract, video, outline, instruction material or other disclosure of Project Intellectual Property, in printed, electronic, oral or other form and Publish has a corresponding meaning;

      Project means the research project and
          activities described in the Details including the creation of Project Intellectual Property, completed in accordance with this agreement;

      Project Completion Date means the scheduled
          completion date for the Project specified in the Details;

      Project IP means all Intellectual Property
          Rights created or developed as part of performing  the Project, but does not include Intellectual Property Rights in Background Intellectual Property;

      Project Obligations of a party means that
          party’s obligations in relation to the Project as specified in Schedule 2;

      Project Start Date means the start date for
          the Project specified in the Details;

      Specified Personnel means those personnel
          specified in the Schedules to perform the Project;

      
        Page 12

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      Student means a student who is enrolled at UNSW
          or the Collaborating Organisation(s) and involved in the Project;

      Tax Invoice has the same meaning as in the GST
          Law;

      Taxable Supply has the same meaning as in the
          GST Law; and

      Total Contribution of a party means the aggregate of the Cash Contribution and in-kind contribution to the Project as specified in Schedule 2.

      	20.2	
              Unless that context otherwise requires:

            

      	

            	(a)	
              a word which denotes the singular denotes the plural and vice versa;

            

      	

            	(b)	
              where a word or phrase is given a particular meaning, other parts of speech and grammatical forms of that word or phrase have corresponding meanings;

            

      	

            	(c)	
              a reference to any legislation includes that legislation as amended, re-enacted consolidated or substituted;

            

      	

            	(d)	
              a reference to a person includes a partnership and a body whether corporate or otherwise;

            

      	

            	(e)	
              any use of the verb ‘includes’, or of words such as ‘for example’ or ‘such as’, do not limit anything else that is included in general speech; and

            

      	

            	(f)	
              a reference to a thing or amount is a reference to the whole and each part of it.

            

      	20.3	
              This agreement may not be construed adversely to a party just because that party prepared it.

            

      	20.4	
              If there is any inconsistency between the terms and conditions of this agreement and the provisions of a schedule or annexure to this agreement, the terms and conditions of the agreement will prevail as between those terms and the
                provisions of the schedule will prevail as between the schedule and the annexure.

            

      

      

      
        Page 13

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      

      

      

      

      Executed as an agreement

      

      

      
        	
                Signed for and on behalf of the University of New South Wales by:

                 

                

              	 
	
                /s/ Debbie Docherty

              	 
	
                Signature

                 

                

              	 
	
                Debbie Docherty

              	 
	
                Name (please print)

                 

                

                Manager, Research Grants and Contracts

              	 
	
                Position

                 

                

                04/06/2022

              	 
	
                Date of signing

              	 

      

      

      

      
        Page 14

        
          

      

      
        	
                Signed for and on behalf of the Medlab Clinical Ltd by :

                 

                

              
	
                /s/ Kerem Kaya

              	 
	
                Signature

                 

                

              	 
	
                Kerem Kaya

              	 
	
                Name (please print)

                 

                

                CFO

              	 
	
                Position

                 

                

                04/04/2022

              	 
	
                Date of signing

              	 

      

      

      

      

      

      

      

      
        Page 15

        
          

      

      

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

          

          

        

      

      

      

      

      

      
        	
                Signed for and on behalf of Macquarie University by :

                 

                

              	 
	
                /s/ Dr Ross McLennan

              	 
	
                Signature

                 

                

              	 
	
                Dr Ross McLennan

              	 
	
                Name (please print)

                 

                

                Pro Vice-Chancellor, Research Services

              	 
	
                Position

                 

                

                04 April 2022

              	 
	
                Date of signing

              	 

      

      

      

      

      

      

      

      By signing this agreement, each signatory warrants that they have authority to enter into this agreement on behalf of the party they are stated to represent.

       

        

      

      

      
        Page 16

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

        

      

       

      

       

      

      Schedule 1 – Party Details

      
        	
                The University of New South Wales/Administering Organisation

              
	
                UNSW

              	
                The University of New South Wales ABN 57 1295 873 179, a body corporate established pursuant to the University of New South Wales Act 1989 (NSW) of UNSW Sydney NSW 2052 Australia

              
	
                Notices

              	
                Attention: Director, Research Grants and Contracts

                Address: The University of New South Wales, UNSW Sydney NSW 2052

                email: rgc@unsw.edu.au

              

      

      Medlab Clinical Ltd/Partner Organisation

      

      

      
        	
                Medlab Clinical Ltd

              	
                ABN 51 169 149 071

              
	
                Notices

              	
                Attention:  Dr Sean Hall/CEO

                Address:  Unit 5A, 11 Lord Street, Botany NSW 2019

                Fax:  N/A

                Email:  sean_hall@medlab.co

              

      

      Macquarie University/Collaborating Organisation

      

      

      
        	
                Macquarie University

              	
                ABN 90 952 801 237

              
	
                Notices

              	
                Attention:  Dr Ross McLennan, Pro Vice-Chancellor, Research Services

                Address: Ground Floor 16 Wally’s Walk Macquarie University NSW 2109

                Email: research.postaward@mq.edu.au

              

      

      

      

      

      

      
        Page 17

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

       

      

      Schedule 2 – Obligations, Contributions and Budget

      
        	
                Project Obligations

              
	
                Role

              	
                As set out in the Project Plan.

              
	
                Specified Personnel

              	
                Pall Thordarson, Chief Investigator

              
	
                UNSW’s Background Intellectual Property

              	
                None specified.

              

      

      

      

      

      

      
        Partner Organisation(s)

        Medlab Clinical Ltd

         

        

        	
                Project Obligations

              
	
                Role

              	
                As set out in the Project Plan.

              
	
                Specified Personnel

              	
                Luis Vitetta, Director of Medical Research

              
	
                Partner Organisation Background Intellectual Property

              	 
	
                Special Conditions

              
	
                Total of $50,000 to be contributed through Investment COVID-19 R&D Fund Tech Voucher scheme, total $50,000 to be contributed through Partner Organisation’s cash
                  contributions. UNSW will send separate invoices to the Partner Organisation for the respective contributions per the below table:

              
	 	
                Milestone

              	
                Investment NSW funds

              	
                Medlab funds

              
	 	
                Execution of agreement

              	
                $25,000

              	
                $25,000

              
	 	
                Completion of project

              	
                $25,000

              	
                $25,000

              
	
                Total Contributions & Payment Milestones

              
	
                Cash Contribution

              	
                Invoices for the cash contributions will be raised in accordance with special conditions above, clause 4.2, and as per payment Milestones:

              
	 	
                Date Due/Milestone

              	
                Fee in AUD$ (GST exclusive)

              
	 	
                Execution of Agreement

              	
                $50,000

              
	 	
                Completion of project

              	
                $50,000

              
	 	
                Subtotal

              	
                $100,000

              
	 	
                GST

              	
                $10,000

              
	 	
                Total including GST

              	
                $110,000

              
	
                In-kind Contributions

              	 

        

        

        

        

        

        

        Collaborating Organisation(s)

        Macquarie University

         

        

        	
                Project Obligations

              
	
                Role

              	
                As set out in the Project Plan.

              
	
                Specified Personnel

              	
                Prof Daniela Traini

              
	
                Collaborating Organisation’s Background Intellectual Property

              	
                N/A

              
	
                Cash Contribution from Administering Organisation to Collaborating Organisation

              
	
                As per clause 4.3, and as per payment Milestone:

              
	
                Date Due/Milestone

              	
                Fee in AUD$ (GST exclusive)

              	 
	
                Execution of Agreement

              	
                $25,000

              	 
	
                Completion of project

              	
                $25,000

              	 
	
                Subtotal

              	
                $50,000

              	 
	
                GST

              	
                $5,000

              	 
	
                Total including GST

              	
                $55,000

              	 
	 
	
                Total Contributions

              
	
                In-kind Contributions

              	
                In-kind contribution of 0.1FTE, use of facilities and equipment

                 

              

        

        

      

      

    

    
      
        Page 18

        
          

      

      
        
          

          

          Collaborative Research Agreement
            

          

          

        

      

      Schedule 3 – Project Plan

      

      

    

    

    

    

  

  Page 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]